FOLFIRI Versus Irinotecan as Second-line Treatment in Metastatic Colorectal Cancer Patients
This study is designed to compare the efficacy and safety of FOLFIRI regimen with irinotecan monodrug in the treatment of advanced colorectal cancer patients in the second-line setting.
Colorectal Carcinoma
DRUG: Irinotecan|DRUG: 5-fluorouracil|DRUG: Leucovorin
progression free survival, 2 months
overall survival, 6 months|overall response rate, 2 months|Number of Participants with Adverse Events, 2 months|quality of life questionnaire, 2 months
This study is designed to compare the efficacy and safety of FOLFIRI regimen with irinotecan monodrug in the treatment of advanced colorectal cancer patients in the second-line setting.